KuDOS/Novacea: Pooling Biotech Resources
Executive Summary
KuDOS Pharmaceuticals' first out-licensing deal appears disappointing: the UK biotech has neither signed an established cancer player nor secured a significant upfront fee for its potentially first-in-class cancer compound, in a hot area of research. But the point of the deal is not to bolster KuDOS' cash coffers, rather, to combine the resources of two biotechs to investigate the drug's potential in a broader range of indications than either company could do alone.